Your session is about to expire
← Back to Search
Mepilex Ag vs. Xeroform in Pediatric Patients That Sustain Partial Thickness Burn Injury
N/A
Waitlist Available
Research Sponsored by Wayne State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up burn injury healing time; up to 10 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial compares two types of dressings, Xeroform and Mepilex Ag, for children with burns on their arms or legs. The goal is to see which dressing helps heal better, causes less pain, and is more comfortable for the child. Mepilex Ag, a special foam dressing, was introduced in 2007 and has shown significant improvement in the treatment of pediatric burns.
Eligible Conditions
- Burns
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ burn injury healing time; up to 10 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~burn injury healing time; up to 10 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Scar Evaluation
Secondary study objectives
Dressing Change Survey
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Mepilex Ag InterventionExperimental Treatment1 Intervention
A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with Mepilex Ag; the product being tested.
Group II: Xeroform ControlActive Control1 Intervention
A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with xeroform dressing, which is the standard of care.
Find a Location
Who is running the clinical trial?
Wayne State UniversityLead Sponsor
314 Previous Clinical Trials
110,897 Total Patients Enrolled
Elika Ridelman, PhDStudy Director - Wayne State University
Wayne State University